EX-10.3 5 b86941exv10w3.htm EX-10.3 exv10w3
Exhibit 10.3
AMENDMENT NO. 2 TO THE
PATENT AND TECHNOLOGY LICENSE AGREEMENT
     This AMENDMENT NO. 2 to the Exclusive PATENT AND TECHNOLOGY LICENSE AGREEMENT between the PARTIES dated September 11, 2006, as amended on December 21, 2007 (the “LICENSE AGREEMENT”), effective the 3rd day of September, 2008 (which is the date this AMENDMENT NO. 2 has been fully executed by all PARTIES), is made by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an institution of higher learning within the Department of Defense, an agency of the United States Government, located at 4301 Jones Bridge Road, Bethesda, Maryland 20814-4779; and (3) APTHERA, INC. (formerly known as ADVANCED PEPTIDE THERAPEUTICS, INC.; hereafter referred to as “LICENSEE”). BOARD, HJF and LICENSEE may be referred to herein collectively as the “PARTIES”.
RECITALS
A.   The LICENSE AGREEMENT requires LICENSEE to achieve certain performance milestones within a specified period of time.
 
B.   BOARD and HJF desire to provide LICENSEE with additional time in which to complete those performance milestones.
 
C.   Accordingly, BOARD, HJF and LICENSEE desire to amend the LICENSE AGREEMENT pursuant to the terms and conditions set forth herein.
     NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the PARTIES hereby agree to the following:

1

 

AMENDMENT
1.   Section 13.3(c) of the LICENSE AGREEMENT shall be deleted in its entirety and replaced with the following:
  13.3   (c) upon thirty (30) calendar days written notice from UTMDACC, if LICENSEE fails to commence a Phase II Clinical Trial or Phase III Clinical Trial in the United States or the European Union on or before September 30, 2009, unless, before the end of such thirty (30) day period, LICENSEE provides evidence satisfactory to UTMDACC that it has commenced the Clinical Trial; or
2.   Section 13.3(d) of the LICENSE AGREEMENT shall be deleted in its entirety and replaced with the following:
  13.3   (d) upon thirty (30) calendar days written notice from UTMDACC, if LICENSEE fails to acquire at least seven million dollars ($7,000,000.00) in funding (whether by debt, equity, merger, reverse merger, grant, corporate partnering or sublicensing) and provides evidence of same to UTMDACC on or before February 28, 2009; or
3.   The PARTIES acknowledge and agree that, except as set forth in this AMENDMENT NO. 2 the terms and conditions of the LICENSE AGREEMENT shall remain unchanged and in full force and effect; provided, however, that nothing contained in the LICENSE AGREEMENT shall have the effect of preventing or limiting, in any way, the terms of this AMENDMENT NO. 2. If any conflict arises between the terms of this AMENDMENT NO. 2 and the terms of the LICENSE AGREEMENT, this AMENDMENT NO. 2 shall govern as to the conflicting terms.
 
4.   This AMENDMENT NO. 2 shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, administrators, executors, successors, and assigns.
 
5.   This AMENDMENT NO. 2 may be executed in one or more counterparts, each of which shall be considered an original, but all of which together shall be deemed to be one and the same document.
[REMINDER OF PAGE INTENTIONALLY BLANK]

2

 

     IN WITNESS WHEREOF, the PARTIES hereto have caused their duly authorized representatives to execute this AMENDMENT NO 2.
             
BOARD OF REGENTS OF THE   APTHERA, INC.
UNIVERSITY OF TEXAS SYSTEM        
 
By  /s/ John Mendelsohn, M.D.   By  /s/ Robert E. Kennedy
  Name:  John Mendelsohn, M.D. President     Name:  Robert E. Kennedy
  Title: The University of Texas     Title: President and CFO
  M. D. Anderson Cancer Center  
Date: 8/4/08
Date: 9/3/08
             
THE UNIVERSITY OF TEXAS   THE HENRY M. JACKSON FOUNDATION FOR
M. D. ANDERSON CANCER CENTER   THE ADVANCEMENT OF MILITARY MEDICINE, INC.
 
By  /s/ Leon Leach   By  /s/ John W. Lowe
  Leon Leach     John W. Lowe
  Executive Vice President     President
  The University of Texas
M. D. Anderson Cancer Center
Date: 8/5/08
Date: 8/27/08
         
Approved as to Content:
 		  
By   /s/ Christopher C. Capelli      
  Christopher C. Capelli   
  Vice President, Technology Transfer M. D. Anderson Cancer Center   
 
Date: 8/17/08

3